GlassScriptPhysician profile
Ahmed E Elahmady
NPI 1265412803
$5,417.86
in general payments reported to CMS, 2019-2025
6 companies · $5,190 in 2025
The $5,190 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.00 · 2021: $141 · 2022: $13.00 · 2024: $23.56 · 2025: $5,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,190 · Food and Beverage: $23.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,190.30 |
| Food and Beverage | $23.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $5,190.30 | 2025 | Disposable Biopsy Forceps |
| Aesculap, INC. | $99.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 | |
| Mauna Kea Technologies, INC. | $37.82 | 2021-2024 | |
| Braintree Laboratories, INC. | $27.07 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Elahmady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.